Feinstein Institutes Launches Pilot Trial to Reduce Cardiovascular Disease in Black Community


Receive instant alerts for news on your actions. Claim your 1-week free trial for Street Insider Premium here.

With support from TD Bank, clinical trial will use smart prescription vials to study treatment adherence

MANHASSET, NY – (BUSINESS WIRE) – The Feinstein Institutes for Medical Research, the scientific arm of Northwell Health, recently received a $ 150,000 grant from TD Bank, America’s Most Convenient Bank®, to launch a new program research and the first trial to reduce cardiovascular disease (CVD) in the black community and determine the best behavioral interventions to reduce cardiovascular disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005126/en/

Mark Butler, PhD, is the principal investigator of the new trial using smart prescription vials. (Credit: Feinstein Institutes)

Adherence to medication is critical to improving health, yet 50% of prescriptions filled in the United States are taken incorrectly. CVD disproportionately affects the black community, but this disparity could be corrected by increasing adherence to protocols for taking potentially life-saving drugs.

The fully virtual trial will initially recruit 42 participants and integrate prescription vials with smart technologies, which will collect data on dose and when cholesterol lowering drugs and statins are taken orally. The data will prompt text messages to remind or encourage users to stick to their drug regimen.

“Cardiovascular disease is a major cause of death, especially among people in the black community. Understanding how to promote adherence to life-saving drugs is one of the best ways to reduce this disparity, ”said Mark Butler, PhD, associate researcher at the Institute of Health System Science and principal investigator of the new trial. “With the support of TD Bank and colleagues across the healthcare system, we hope to determine the best intervention strategies to help people stick to prescribed treatments and improve their cardiovascular health.

“To improve outcomes for healthcare for all, we need to identify innovative solutions that correct the inequalities that currently exist,” said Emmet Conlon, chief healthcare officer at TD Bank. “We know that cardiovascular disease has a different impact on the black community. We hope that through this investment, we can help identify ways to address inequalities and improve health outcomes for vulnerable populations.”

The main objective of the trial is to increase treatment adherence by at least 20% using SMS interventions to reduce CVD disparities. In addition, the team will collect data on the ideal “intervention dose” – the most beneficial frequency of text messages needed to significantly increase treatment adherence. The essay’s text message signals will use a multi-behavioral change technique (BCT) intervention, which incorporates behavioral feedback, monitoring, goal setting, action planning, and prompts to encourage positive health behavior. For example, a participant may receive the text message “Did you take your medications as prescribed today?” Requiring a “Yes” or “No” response, ideally inducing positive behavior.

This TD Bank grant supports Northwell’s Go beyond the impossible campaign, a billion-dollar global fundraising effort to fuel innovation to advance healthcare and support Northwell’s promise to the people it serves. The campaign – which supports capital projects, improves hospitals and clinical programs, advances research, and funds teaching and research initiatives – was launched publicly in October 2018 and has so far garnered more of $ 900 million.

“Through TD Ready Commitment, the Bank’s corporate citizenship platform, we are making community investments that support the changes needed to help create a more inclusive and sustainable future,” said Shelley Sylva, Chief Citizenship Officer of company in the United States at TD Bank. “But we cannot create this more sustainable and inclusive future without addressing racial disparities in health care access and outcomes. That is why I am delighted to support this innovative new research that will help identify ways to ensuring that vulnerable communities are not being left behind when it comes to getting the care they need. ”

“Closing health disparities will increase the equity and quality of health care for our communities,” said Kevin J. Tracey, MD, President and CEO of the Feinstein Institutes and Distinguished Family Chair Karches in medical research. “This support from TD Bank will allow Dr. Butler to shed new light on technologies to influence behavioral interventions for cardiovascular disease.

The Institute of Health System Science, led by Karina Davidson, PhD, Donald and Barbara Zucker Professor of Health Outcomes, is a multidisciplinary team of scientists and clinicians whose research efforts are focused on the development of evidence-based interventions. evidence often using new technologies to improve health. results for individuals, organizations and communities.

More recently, the Institute of Health System Science announced the hiring of Felicia Hill-Briggs, PhD to help lead and expand disease prevention research. Dr Hill-Briggs was named the Emeritus Simons Chair in Clinical Research in October. Additionally, recently announced Edith Burns, MD, received $ 1.6 million from the National Institutes of Health’s National Institute on Aging to support a trial to expand the use of video, educational materials and a specialist. palliative care educators to optimize patient-centered care goals. Planning.

About the Feinstein institutes

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest healthcare provider and private employer in New York State. Home to 50 research laboratories, 3,000 clinical research studies and 5,000 researchers and employees, the Feinstein Institutes raise the level of medical innovation through its five institutes of behavioral sciences, bioelectronic medicine, cancer, human sciences. health and molecular medicine systems. We are making breakthroughs in genetics, oncology, brain research, mental health, autoimmunity and are the global scientific leader in bioelectronic medicine, a new field of science that has the potential to revolutionize medicine. For more information on how we generate knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Matthieu libassi


[email protected]

Source: Feinstein Institutes for Medical Research

Source link


Comments are closed.